Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Antibodies, Monoclonal"
journalStr:"The Lancet. Oncology"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
PubPharm (171)
1
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas : a single-centre phase 2 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Somaiah, N.
|
Conley, A.
|
Parra, E.
| +29
CommentIn: Lancet Oncol. 2022 Sep;23(9):1111-1112. - PMID 36055298
Wird geladen...
2
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer
enthalten in:
The Lancet. Oncology
| 2022
von
Recondo, G.
|
Mezquita, L.
CommentOn: Lancet Oncol. 2022 Jun;23(6):781-792. - PMID 35576957
Wird geladen...
3
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Wang, J.
|
Zhou, C.
|
Yao, W.
| +79
CommentIn: Lancet Oncol. 2022 Jun;23(6):692-693. - PMID 35576958
Wird geladen...
4
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE) : primary and follow-up analyses of a randomised, double-blind, phase 2 study
enthalten in:
The Lancet. Oncology
| 2022
von
Cho, B.
|
Abreu, D.
|
Hussein, M.
| +16
CommentIn: Nat Rev Clin Oncol. 2022 Jul;19(7):428. - PMID 35606416
Wird geladen...
5
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy : an open-label, multicentre, randomised, phase 2 trial
enthalten in:
The Lancet. Oncology
| 2022
von
Schoenfeld, J.
|
Giobbie-Hurder, A.
|
Ranasinghe, S.
| +34
CommentIn: Lancet Oncol. 2022 Feb;23(2):191-193. - PMID 35033225
Wird geladen...
6
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010) : a multicentre, open-label, randomised, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Bellmunt, J.
|
Hussain, M.
|
Gschwend, J.
| +24
CommentIn: Lancet Oncol. 2021 Jun;22(6):e236. - PMID 34087145
Wird geladen...
7
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Lee, N.
|
Ferris, R.
|
Psyrri, A.
| +18
CommentIn: Lancet Oncol. 2021 Jul;22(7):e290. - PMID 34197752
Wird geladen...
8
Combination treatment options for small-cell lung cancer - Authors' reply
enthalten in:
The Lancet. Oncology
| 2021
von
Goldman, J.
|
Paz-Ares, L.
CommentOn: Lancet Oncol. 2021 Jan;22(1):51-65. - PMID 33285097
Wird geladen...
9
Combination treatment options for small-cell lung cancer
enthalten in:
The Lancet. Oncology
| 2021
von
Horita, N.
|
Katakura, S.
|
Takeshi, K.
CommentOn: Lancet Oncol. 2021 Jan;22(1):51-65. - PMID 33285097
Wird geladen...
10
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2021
von
Goldman, J.
|
Dvorkin, M.
|
Chen, Y.
| +123
CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Antibodies, Monoclonal
Filter aufheben
Zeitschrift: The Lancet. Oncology
Medienart
171
Aufsätze
137
E-Artikel
137
E-Ressourcen
34
Gedruckte Aufsätze
Zeitschriftentitel
The Lancet. Oncology
Thema
Antibodies, Monoclonal
171
Antibodies, Monoclonal, Humanized
98
Journal Article
73
Antineoplastic Agents
57
Research Support, Non-U.S. Gov't
49
Comment
41
Multicenter Study
40
EC 2.7.10.1
39
2S9ZZM9Q9V
39
Bevacizumab
37
Randomized Controlled Trial
33
Letter
33
News
32
Cetuximab
32
PQX0D8J21J
23
Clinical Trial, Phase II
23
P188ANX8CK
23
Trastuzumab
19
Angiogenesis Inhibitors
18
Clinical Trial, Phase III
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
17
2020-
104
2010-2019
48
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
171
Englisch
Haven't found what you're looking for?
Wird geladen...